Cargando…

It can be dangerous to take epidemic curves of COVID-19 at face value

During an epidemic with a new virus, we depend on modelling to plan the response: but how good are the data? The aim of our work was to better understand the impact of misclassification errors in identification of true cases of COVID-19 on epidemic curves. Data originated from Alberta, Canada (avail...

Descripción completa

Detalles Bibliográficos
Autores principales: Burstyn, Igor, Goldstein, Neal D., Gustafson, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309693/
https://www.ncbi.nlm.nih.gov/pubmed/32578184
http://dx.doi.org/10.17269/s41997-020-00367-6
_version_ 1783549248031162368
author Burstyn, Igor
Goldstein, Neal D.
Gustafson, Paul
author_facet Burstyn, Igor
Goldstein, Neal D.
Gustafson, Paul
author_sort Burstyn, Igor
collection PubMed
description During an epidemic with a new virus, we depend on modelling to plan the response: but how good are the data? The aim of our work was to better understand the impact of misclassification errors in identification of true cases of COVID-19 on epidemic curves. Data originated from Alberta, Canada (available on 28 May 2020). There is presently no information of sensitivity (Sn) and specificity (Sp) of laboratory tests used in Canada for the causal agent for COVID-19. Therefore, we examined best attainable performance in other jurisdictions and similar viruses. This suggested perfect Sp and Sn 60–95%. We used these values to re-calculate epidemic curves to visualize the potential bias due to imperfect testing. If the sensitivity improved, the observed and adjusted epidemic curves likely fall within 95% confidence intervals of the observed counts. However, bias in shape and peak of the epidemic curves can be pronounced, if sensitivity either degrades or remains poor in the 60–70% range. These issues are minor early in the epidemic, but hundreds of undiagnosed cases are likely later on. It is therefore hazardous to judge progress of the epidemic based on observed epidemic curves unless quality of testing is better understood. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.17269/s41997-020-00367-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7309693
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-73096932020-06-23 It can be dangerous to take epidemic curves of COVID-19 at face value Burstyn, Igor Goldstein, Neal D. Gustafson, Paul Can J Public Health Special Section on COVID-19: Commentary During an epidemic with a new virus, we depend on modelling to plan the response: but how good are the data? The aim of our work was to better understand the impact of misclassification errors in identification of true cases of COVID-19 on epidemic curves. Data originated from Alberta, Canada (available on 28 May 2020). There is presently no information of sensitivity (Sn) and specificity (Sp) of laboratory tests used in Canada for the causal agent for COVID-19. Therefore, we examined best attainable performance in other jurisdictions and similar viruses. This suggested perfect Sp and Sn 60–95%. We used these values to re-calculate epidemic curves to visualize the potential bias due to imperfect testing. If the sensitivity improved, the observed and adjusted epidemic curves likely fall within 95% confidence intervals of the observed counts. However, bias in shape and peak of the epidemic curves can be pronounced, if sensitivity either degrades or remains poor in the 60–70% range. These issues are minor early in the epidemic, but hundreds of undiagnosed cases are likely later on. It is therefore hazardous to judge progress of the epidemic based on observed epidemic curves unless quality of testing is better understood. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.17269/s41997-020-00367-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-06-23 /pmc/articles/PMC7309693/ /pubmed/32578184 http://dx.doi.org/10.17269/s41997-020-00367-6 Text en © The Canadian Public Health Association 2020
spellingShingle Special Section on COVID-19: Commentary
Burstyn, Igor
Goldstein, Neal D.
Gustafson, Paul
It can be dangerous to take epidemic curves of COVID-19 at face value
title It can be dangerous to take epidemic curves of COVID-19 at face value
title_full It can be dangerous to take epidemic curves of COVID-19 at face value
title_fullStr It can be dangerous to take epidemic curves of COVID-19 at face value
title_full_unstemmed It can be dangerous to take epidemic curves of COVID-19 at face value
title_short It can be dangerous to take epidemic curves of COVID-19 at face value
title_sort it can be dangerous to take epidemic curves of covid-19 at face value
topic Special Section on COVID-19: Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309693/
https://www.ncbi.nlm.nih.gov/pubmed/32578184
http://dx.doi.org/10.17269/s41997-020-00367-6
work_keys_str_mv AT burstynigor itcanbedangeroustotakeepidemiccurvesofcovid19atfacevalue
AT goldsteinneald itcanbedangeroustotakeepidemiccurvesofcovid19atfacevalue
AT gustafsonpaul itcanbedangeroustotakeepidemiccurvesofcovid19atfacevalue